Mutations in voltage-gated sodium channels such as Nav1.7 have been implicated in painful DN, and are the target of antagonists such as the drug Xenon402, which is useful in erythromelalgia and has the potential to be used in other types of neuropathic pain (158,159). The gene discussed is SCN9A; the disease is liver dysplastic nodule.